Genmab A/S continued to derive significant revenue from partnerships with large pharma companies in 2022 while investing heavily in proprietary product development. Revenue grew to DKK 14.59 billion (€1.96 billion) in the year, up by 72% from a year earlier. The Danish company spent DKK 5.562 billion, or 38% of this revenue, on research and development.
